Cargando…

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

Imiquimod is an orally active interferon inducer with anti-tumour activity in experimental animals. In this study the tolerability, toxicity and biological effects of daily oral imiquimod administration were investigated in 21 patients with refractory cancer. Patients were treated with doses of 25 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savage, P., Horton, V., Moore, J., Owens, M., Witt, P., Gore, M. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074776/ https://www.ncbi.nlm.nih.gov/pubmed/8912549

Ejemplares similares

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
por: Šutalo, S., et al.
Publicado: (2015)

Miscellaneous Antiviral Agents (Interferons, Imiquimod, Pleconaril)
por: Dolin, Raphael
Publicado: (2015)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
por: Daayana, S, et al.
Publicado: (2010)

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
por: Bilenker, J H, et al.
Publicado: (2004)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
por: Ruiz‐Huertas, Pedro, et al.
Publicado: (2022)

Interferon I 1979
por: Moore, M.
Publicado: (1980)

Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1
por: Takase, Yuuki, et al.
Publicado: (2021)

Melanoma Arising after Imiquimod Use
por: Paul, Sharad P.
Publicado: (2014)

Imiquimod (Aldara cream).
por: Buck, H W
Publicado: (1998)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Topical imiquimod yields systemic effects due to unintended oral uptake
por: Grine, Lynda, et al.
Publicado: (2016)

Topical imiquimod for the palliative treatment of recurrent oral squamous cell carcinoma
por: Wester, Annie, et al.
Publicado: (2017)

Molecular docking analysis of imiquimod with the TGF-β targets for oral carcinoma
por: Pazhani, Jayanthi, et al.
Publicado: (2023)

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings
por: Tartour, E, et al.
Publicado: (2000)

Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model
por: Assil, Salma, et al.
Publicado: (2023)

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial
por: Teulings, Hansje-Eva, et al.
Publicado: (2018)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer
por: Hoff, P M, et al.
Publicado: (2008)

A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days
por: Cohen, Craig R., et al.
Publicado: (2011)

Imiquimod Boosts Interferon Response, and Decreases ACE2 and Pro-Inflammatory Response of Human Bronchial Epithelium in Asthma
por: Nieto-Fontarigo, Juan José, et al.
Publicado: (2021)

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
por: Spreafico, A, et al.
Publicado: (2015)

A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Carmichael, J., et al.
Publicado: (1990)

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
por: Smith, Katherine E. R., et al.
Publicado: (2023)

Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice
por: Zaki, Leila, et al.
Publicado: (2020)

Imiquimod for the treatment of genital warts: a quantitative systematic review
por: Moore, R Andrew, et al.
Publicado: (2001)

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
por: Chen, X, et al.
Publicado: (2003)

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects
por: Lee, Kok-Onn, et al.
Publicado: (2017)

No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis
por: Marcus, Julia L., et al.
Publicado: (2013)

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours
por: de Jonge, M J A, et al.
Publicado: (2004)

Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial
por: Koeneman, M. M., et al.
Publicado: (2017)

Topical Imiquimod Treatment of Lentigo Maligna
por: Ventura, F., et al.
Publicado: (2009)

Bowen's Disease Treated with Imiquimod and Cryotherapy
por: Patel, Krina B
Publicado: (2012)

Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial
por: Fonseca, Bruno O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ou52ipqp7v47h1q4dvn5e74cvf